2003
DOI: 10.1038/nrc992
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Ionizing radiation (IR) has proven to be a powerful medical treatment in the fight against cancer. Rational and effective use of its killing power depends on understanding IR-mediated responses at the molecular, cellular and tissue levels. Tumour cells frequently acquire defects in the molecular regulatory mechanisms of the response to IR, which sensitizes them to radiation therapy. One of the key molecules involved in a cell's response to IR is p53. Understanding these mechanisms indicates new rational approa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

12
421
0
3

Year Published

2005
2005
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 496 publications
(436 citation statements)
references
References 105 publications
12
421
0
3
Order By: Relevance
“…To determine whether these metabolic changes correlated with radiation sensitivity in mice, TUNEL assays were performed to assess cell death in the spleen and small intestine, two radiosensitive tissues. 33 Treatment with 2 Gy irradiation induced massive apoptosis in the spleen and small intestine, which was markedly reduced by a proceeding dose of 0.1 Gy (Figures 6d and e). Importantly, treatment of mice with 2-DG (200 mg/kg) largely abolished the 0.1 Gy-induced resistance to high-dose irradiation in these tissues (Figures 6d and e).…”
Section: Resultsmentioning
confidence: 93%
See 1 more Smart Citation
“…To determine whether these metabolic changes correlated with radiation sensitivity in mice, TUNEL assays were performed to assess cell death in the spleen and small intestine, two radiosensitive tissues. 33 Treatment with 2 Gy irradiation induced massive apoptosis in the spleen and small intestine, which was markedly reduced by a proceeding dose of 0.1 Gy (Figures 6d and e). Importantly, treatment of mice with 2-DG (200 mg/kg) largely abolished the 0.1 Gy-induced resistance to high-dose irradiation in these tissues (Figures 6d and e).…”
Section: Resultsmentioning
confidence: 93%
“…Indeed, exposure of whole animals to 0.1 Gy radiation resulted in a robust induction of HIF1a and GLUT-3 expression in the small intestine (Figure 6a), a tissue that is particularly susceptible to the damaging effects of radiation. 33 Imaging of live animals with FDG-PET demonstrated a clear increase in glucose uptake specific to mice irradiated with 0.1 Gy or 0.1 Gy followed by 2 Gy, but not in sham-treated or 2 Gy-treated mice (Figures 6b and c). To determine whether these metabolic changes correlated with radiation sensitivity in mice, TUNEL assays were performed to assess cell death in the spleen and small intestine, two radiosensitive tissues.…”
Section: Resultsmentioning
confidence: 97%
“…[1][2][3][4] This happens because there are differences in the response to these therapies due, at least in part, to the heterogeneity in expression of genes linked to chemoresistance and radioresistance, where the tumor suppressor gene p53 has a very important role. 5,6 Thus, it is important to find diagnostic tools to identify these genetic differences in order to develop more personalized therapies and increase the therapeutic success.…”
mentioning
confidence: 99%
“…Ionizing radiation also induces a variable degree of apoptosis in tumor cells, with the extent of apoptosis correlated directly with antitumor efficacy of radiation therapy. 30,31 Especially in normal cells, p53-mediated apoptosis is an important factor in determining sensitivity to ionizing radiation. 31 Moreover, p53 mutation status has to be examined before using the PG 13 -Bcl-2 plasmid, because this strategy can not be applied to patients carrying tumors with wt p53.…”
Section: Discussionmentioning
confidence: 99%
“…30,31 Especially in normal cells, p53-mediated apoptosis is an important factor in determining sensitivity to ionizing radiation. 31 Moreover, p53 mutation status has to be examined before using the PG 13 -Bcl-2 plasmid, because this strategy can not be applied to patients carrying tumors with wt p53. However, p53-mutation is associated with increased risk of distant metastasis and poor prognosis in breast 11 and lung cancer, 32 and those patients may need to be received intensive treatment.…”
Section: Discussionmentioning
confidence: 99%